Cencora, Inc. $COR Stake Lifted by Truist Financial Corp

Truist Financial Corp lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 3.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 402,357 shares of the company’s stock after acquiring an additional 11,692 shares during the quarter. Truist Financial Corp’s holdings in Cencora were worth $125,749,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in COR. Phoenix Financial Ltd. raised its stake in shares of Cencora by 31.9% in the 3rd quarter. Phoenix Financial Ltd. now owns 1,137 shares of the company’s stock worth $355,000 after buying an additional 275 shares in the last quarter. Belpointe Asset Management LLC lifted its holdings in Cencora by 1.0% in the 3rd quarter. Belpointe Asset Management LLC now owns 7,156 shares of the company’s stock valued at $2,237,000 after acquiring an additional 73 shares during the last quarter. Alta Advisers Ltd boosted its position in shares of Cencora by 9.1% during the 3rd quarter. Alta Advisers Ltd now owns 843 shares of the company’s stock valued at $263,000 after purchasing an additional 70 shares in the last quarter. Purkiss Capital Advisors LLC grew its stake in shares of Cencora by 7.0% in the 3rd quarter. Purkiss Capital Advisors LLC now owns 1,171 shares of the company’s stock worth $366,000 after purchasing an additional 77 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of Cencora by 1.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 33,883 shares of the company’s stock worth $10,590,000 after purchasing an additional 377 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Cencora Stock Up 0.2%

Cencora stock opened at $356.15 on Wednesday. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 1-year low of $237.71 and a 1-year high of $377.54. The firm’s fifty day simple moving average is $348.17 and its 200-day simple moving average is $323.06. The company has a market capitalization of $69.09 billion, a P/E ratio of 44.80, a P/E/G ratio of 1.69 and a beta of 0.66.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the business posted $3.34 earnings per share. The business’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is 30.19%.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the transaction, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. This trade represents a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have issued reports on COR. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Mizuho increased their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Finally, Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $393.08.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.